Navigation Links
Near IR capability of the FluoroLog


Introduction
The SPEX FLUOROLOG spectrofluoro-meter, with its modular flexibility, gives choice of gratings, detectors, and other accessories. The standard FLUOROLOG configuration has an R928P photomultiplier tube in an L-format, and is sensitive out to ~ 850 nm. For near-IR fluores-cence measurements, an optional solid-state de-tector (DSS-IGA020L) can be substituted for the R928P, or mounted on the T-side of the sample compartment. The DSS-IGA020L is an InGaAs detector, with sensitivity to ~1700 nm. This Application Note demonstrates the ability of the FLUOROLOG to detect fluorescence emissions in the near-IR.


Experiment
A liquid-N2-cooled DSS-IGA020L In-GaAs detector was used on the T-side of a FLUOROLOG-321 (single emission mono-chromator). The gratings groove density was 600 grooves mm1, blazed to 1.0 m. Samples were Nd-doped phosphate laser glass, and Er2O3 powder. The integration time was 0.2 s. Scan-ning parameters are in Table 1 (see back).


Results
Figure 1 (Nd-doped glass, below) shows clear peaks in the red and near-IR regions. Fig-ure 2 (on back) shows spectra for Er2O3 powder in a Model 1933 solid-sample holder. A 780-nm cut-off filter was used in the emission spectrum. Obvious near-IR bands are visible at ~1000 nm and ~1500 nm.


Conclusion
The FLUOROLOG is a sensitive in-strument for all fluorescence applications in the liquid or solid state. With its ability to add detec-tors easily, the full range of fluorescence, from UV to near-IR, is available for all your fluores-cence needs.




back to top


'"/>

Source:


Page: All 1

Related biology technology :

1. FluoroMax multiwavelength capability
2. Wideband sensitivity of the FluoroLog-3
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Near capability the FluoroLog

Breaking Biology Technology:Lyric Presents the Sounds of the Season 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4